Congenital Adrenal Hyperplasia (CAH) Market to Register Stunning Growth During the Forecast Period (2022-2032) – DelveInsight | Key Companies – Adrenas Therapeutics, Diurnal Group

 Breaking News
  • No posts were found

Congenital Adrenal Hyperplasia (CAH) Market to Register Stunning Growth During the Forecast Period (2022-2032) – DelveInsight | Key Companies – Adrenas Therapeutics, Diurnal Group

Congenital Adrenal Hyperplasia (CAH) Market to Register Stunning Growth During the Forecast Period (2022-2032) - DelveInsight | Key Companies - Adrenas Therapeutics, Diurnal Group
Delveinsight Business Research LLP

As per DelveInsight, the Congenital Adrenal Hyperplasia market is anticipated to evolve immensely in the coming years owing to the increasing prevalent population of Congenital Adrenal Hyperplasia patients in the 7MM, extensive research and development activities of pharmaceutical companies, the rising awareness of the disease, expansion of therapies into new applications such as pediatric use and better approaches to therapy development across the world and the launch of novel therapies in the market.

Some of the leading players such as Neurocrine Biosciences, Diurnal Limited, Spruce Biosciences, Adrenas Therapeutics, Millendo Therapeutics, Neurocrine Biosciences, BridgeBio Pharma, and others are actively working in the Congenital Adrenal Hyperplasia therapeutics Market.

DelveInsight’s “Congenital Adrenal Hyperplasia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Congenital Adrenal Hyperplasia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Congenital Adrenal Hyperplasia market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Congenital Adrenal Hyperplasia: An Overview

Congenital adrenal hyperplasia (Congenital Adrenal Hyperplasia) is a group of rare inherited autosomal recessive disorders characterized by a deficiency of one of the enzymes needed to make specific hormones. Congenital Adrenal Hyperplasia affects the adrenal glands at each kidney’s top.

The most common cause of Congenital Adrenal Hyperplasia is the absence of the enzyme 21-hydroxylase. Different mutations in the gene are responsible for 21-hydroxylase, which results in different levels of the enzyme, producing a spectrum of effects. 21-hydroxylase deficiency is broken down further into two subcategories: Classical Congenital Adrenal Hyperplasia, which can be subdivided into the Salt-Losing (SL) form or the Simple-Virilizing (SV) form, and Non-Classical Congenital Adrenal Hyperplasia. Classical Congenital Adrenal Hyperplasia is far more severe and can result in adrenal crisis and death if not detected and treated. Non-classical Congenital Adrenal Hyperplasia is milder and may or may not present symptoms

Congenital Adrenal Hyperplasia Market Key Facts

  • According to the NORD, the most common form of Congenital Adrenal Hyperplasia affects approximately 1/10,000–1/15,000 people in the United States and Europe.

  • According to the results of a study by Shmouni et al. (2017), nonclassic Congenital Adrenal Hyperplasia carriership was found in 9.5% of Caucasians. The estimated prevalence of nonclassic Congenital Adrenal Hyperplasia in Caucasians was 1 in 200.

  • According to a study titled by Khalid et al., approximately one child in every 18,000 born in Great Britain has Congenital Adrenal Hyperplasia. Among the studied cases of Congenital Adrenal Hyperplasia, 92% had a 21-hydroxylase deficiency.

  • According to a study by Witchel et al. (2017), the incidence of the classic forms is reported to be in the range from 1:5000 to 1:15,000 and varies among ethnic/racial backgrounds. Additionally, the prevalence of 21-OHD is lower among African-Americans than among Caucasians in the United States.

Congenital Adrenal Hyperplasia Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Congenital Adrenal Hyperplasia market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Congenital Adrenal Hyperplasia market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Congenital Adrenal Hyperplasia Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Congenital Adrenal Hyperplasia Epidemiology, Segmented as –

  • Total Prevalent Cases of Congenital Adrenal Hyperplasia in the 7MM (2019–2032)

  • Total Diagnosed Prevalent Cases of Congenital Adrenal Hyperplasia in the 7MM (2019–2032)

  • Diagnosed Prevalent Cases of Classic and Non-classic Congenital Adrenal Hyperplasia in the 7MM (2019–2032)

Congenital Adrenal Hyperplasia Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Congenital Adrenal Hyperplasia market or expected to be launched during the study period. The analysis covers the Congenital Adrenal Hyperplasia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Congenital Adrenal Hyperplasia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Congenital Adrenal Hyperplasia Market Will Evolve and Grow by 2032 @

Congenital Adrenal Hyperplasia Therapeutics Analysis

Currently, there is no cure for Congenital Adrenal Hyperplasia. However, treatments are available to address some of the associated symptoms. Hitherto, Glucocorticoid therapy (Prednisone, Dexamethasone) aims to replace the missing steroids and reduce adrenal androgens levels, thus promoting the prevention of virilization and menstrual and reproductive function disorders. The choice of an adequate therapeutic dose is based on the 17-OHP physiological range for a certain age. At times of stress, the dose of glucocorticoids given should be increased. 

Several major pharma and biotech companies are actively developing therapies for Congenital Adrenal Hyperplasia. Currently, Diurnal Group is leading the therapeutics market with its Congenital Adrenal Hyperplasia drug candidates in the most advanced stage of clinical development. 

The Leading Companies in the Congenital Adrenal Hyperplasia Therapeutics Market Include:

  • Adrenas Therapeutics

  • Crinetics Pharmaceuticals

  • Diurnal Limited

  • Millendo Therapeutics

  • Neurocrine Biosciences

  • Spruce Biosciences

And Many Others

Congenital Adrenal Hyperplasia Emerging and Marketed Drugs Covered in the Report Include:

  • AAV BBP-631: Adrenas Therapeutics

  • Chronocort: Diurnal Group plc

  • NBI-74788: Neurocrine Biosciences

  • Tildacerfont: Spruce Biosciences

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Congenital Adrenal Hyperplasia Competitive Intelligence Analysis

4. Congenital Adrenal Hyperplasia Market Overview at a Glance

5. Congenital Adrenal Hyperplasia Disease Background and Overview

6. Congenital Adrenal Hyperplasia Patient Journey

7. Congenital Adrenal Hyperplasia Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Congenital Adrenal Hyperplasia Treatment Algorithm, Current Treatment, and Medical Practices

9. Congenital Adrenal Hyperplasia Unmet Needs

10. Key Endpoints of Congenital Adrenal Hyperplasia Treatment

11. Congenital Adrenal Hyperplasia Marketed Products

12. Congenital Adrenal Hyperplasia Emerging Drugs and Latest Therapeutic Advances

13. Congenital Adrenal Hyperplasia Seven Major Market Analysis

14. Attribute Analysis

15. Congenital Adrenal Hyperplasia Market Outlook (In US, EU5, and Japan)

16. Congenital Adrenal Hyperplasia Access and Reimbursement Overview

17. KOL Views on the Congenital Adrenal Hyperplasia Market

18. Congenital Adrenal Hyperplasia Market Drivers

19. Congenital Adrenal Hyperplasia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @


Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States